Review



sting agonist diabzi treatment  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress sting agonist diabzi treatment
    Sting Agonist Diabzi Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sting+agonist+4/pm41259200-337-5-21?v=MedChemExpress
    Average 93 stars, based on 24 article reviews
    sting agonist diabzi treatment - by Bioz Stars, 2026-07
    93/100 stars

    Images



    Similar Products

    93
    MedChemExpress sting agonist diabzi treatment
    Sting Agonist Diabzi Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sting+agonist+4/pm41259200-337-5-21?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    sting agonist diabzi treatment - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress abzi
    Abzi, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sting+agonist+4/pmc12296492-67-0-2?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    abzi - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress sting agonist
    Sting Agonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sting+agonist+4/pm40492586-276-0-5?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    sting agonist - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress sting agonists
    Sting Agonists, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sting+agonist+4/pm39988898-217-13-15?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    sting agonists - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress mitophagy agonist compounds
    Figure 5. Engineering hydrogel therapeutic systems for cell delivery. A) Schematic diagram of the construction of the injectable hydrogel delivery system. This involves mixing a hydrogel mixture with a photoinitiator, CAR-T cells, and a <t>mitophagy</t> agonist (BC1618). The delivery system is then injected into the tumor site and subsequent photocuring with violet light at 405 nm is performed, resulting in the formation of a solidified hydrogel matrix embedded with CAR-T cells that are continuously released into the tumor microenvironment over time. B) Visualization of the growth kinetics of CAR-T-GFP cells within the hydrogel over a 48-hour period, as captured through 3D fluorescence imaging. A total of 1 × 105 CAR-T-GFP cells were encapsulated in the hydrogel, and CAR-T-GFP cell proliferation was measured via 3D fluorescence imaging at 0 h and 48 h. C) Quantification of the proliferation of CAR-T cells within the hydrogel compared with that in the culture medium over a 10-day period. The number of proliferating CAR-T cells cultured in the medium and hydrogel was counted every 10 days, (n = 3). D) The viability of CAR-T cells cultured in either medium or hydrogel over a 10-day period was measured via trypan blue staining, (n = 3). E) The levels of IL-2 and INF-𝛾in CAR-T cells from medium or hydrogel cocultured with MDA-MB-468 cell supernatant (n = 3). F) The number of released CAR-T cells in vitro was counted, (n = 3). G–H) The fluorescent dye for the hydrogel was added to detect the degradation of the hydrogel in vivo for 9 days (H), and the total ROI was measured (G). Representative images of the subcutaneous hydrogel on Days 0 and 9. (C, D, E) The data are shown as the means ± SDs and were analyzed via an unpaired t test. ns: p > 0.05.
    Mitophagy Agonist Compounds, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sting+agonist+4/pm39840546-178-23-29?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    mitophagy agonist compounds - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    Image Search Results


    Figure 5. Engineering hydrogel therapeutic systems for cell delivery. A) Schematic diagram of the construction of the injectable hydrogel delivery system. This involves mixing a hydrogel mixture with a photoinitiator, CAR-T cells, and a mitophagy agonist (BC1618). The delivery system is then injected into the tumor site and subsequent photocuring with violet light at 405 nm is performed, resulting in the formation of a solidified hydrogel matrix embedded with CAR-T cells that are continuously released into the tumor microenvironment over time. B) Visualization of the growth kinetics of CAR-T-GFP cells within the hydrogel over a 48-hour period, as captured through 3D fluorescence imaging. A total of 1 × 105 CAR-T-GFP cells were encapsulated in the hydrogel, and CAR-T-GFP cell proliferation was measured via 3D fluorescence imaging at 0 h and 48 h. C) Quantification of the proliferation of CAR-T cells within the hydrogel compared with that in the culture medium over a 10-day period. The number of proliferating CAR-T cells cultured in the medium and hydrogel was counted every 10 days, (n = 3). D) The viability of CAR-T cells cultured in either medium or hydrogel over a 10-day period was measured via trypan blue staining, (n = 3). E) The levels of IL-2 and INF-𝛾in CAR-T cells from medium or hydrogel cocultured with MDA-MB-468 cell supernatant (n = 3). F) The number of released CAR-T cells in vitro was counted, (n = 3). G–H) The fluorescent dye for the hydrogel was added to detect the degradation of the hydrogel in vivo for 9 days (H), and the total ROI was measured (G). Representative images of the subcutaneous hydrogel on Days 0 and 9. (C, D, E) The data are shown as the means ± SDs and were analyzed via an unpaired t test. ns: p > 0.05.

    Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

    Article Title: Improved Efficacy of Triple-Negative Breast Cancer Immunotherapy via Hydrogel-Based Co-Delivery of CAR-T Cells and Mitophagy Agonist.

    doi: 10.1002/advs.202409835

    Figure Lengend Snippet: Figure 5. Engineering hydrogel therapeutic systems for cell delivery. A) Schematic diagram of the construction of the injectable hydrogel delivery system. This involves mixing a hydrogel mixture with a photoinitiator, CAR-T cells, and a mitophagy agonist (BC1618). The delivery system is then injected into the tumor site and subsequent photocuring with violet light at 405 nm is performed, resulting in the formation of a solidified hydrogel matrix embedded with CAR-T cells that are continuously released into the tumor microenvironment over time. B) Visualization of the growth kinetics of CAR-T-GFP cells within the hydrogel over a 48-hour period, as captured through 3D fluorescence imaging. A total of 1 × 105 CAR-T-GFP cells were encapsulated in the hydrogel, and CAR-T-GFP cell proliferation was measured via 3D fluorescence imaging at 0 h and 48 h. C) Quantification of the proliferation of CAR-T cells within the hydrogel compared with that in the culture medium over a 10-day period. The number of proliferating CAR-T cells cultured in the medium and hydrogel was counted every 10 days, (n = 3). D) The viability of CAR-T cells cultured in either medium or hydrogel over a 10-day period was measured via trypan blue staining, (n = 3). E) The levels of IL-2 and INF-𝛾in CAR-T cells from medium or hydrogel cocultured with MDA-MB-468 cell supernatant (n = 3). F) The number of released CAR-T cells in vitro was counted, (n = 3). G–H) The fluorescent dye for the hydrogel was added to detect the degradation of the hydrogel in vivo for 9 days (H), and the total ROI was measured (G). Representative images of the subcutaneous hydrogel on Days 0 and 9. (C, D, E) The data are shown as the means ± SDs and were analyzed via an unpaired t test. ns: p > 0.05.

    Article Snippet: The most efficacious machine learning algorithms were subsequently curated for refinement and training of a classification model. A mitophagy library consisting of 45 mitophagy agonist compounds was obtained from MCE, and the model was then utilized to assess the bioactivity of 45 extant molecules.

    Techniques: Injection, Imaging, Cell Culture, Staining, In Vitro, In Vivo